"High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis".
BRCA1/2
breast cancer
downstaging
high-risk
screening
survival
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
03
2021
accepted:
03
08
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Germline Retrospectively, we analyzed 346 women diagnosed with breast tumors. Patients were divided according to the timing of Median follow-up times were 131.42 and 93.77 months in the BRCA-preDx awareness and BRCA-postDx awareness groups, respectively. In the BRCA-preDx awareness group, 78.7% of the patients had invasive tumors and 21.3% were diagnosed with pure ductal carcinoma High-risk screening might facilitate downstaging of detected breast tumor among
Sections du résumé
BACKGROUND
BACKGROUND
Germline
PATIENTS AND METHODS
METHODS
Retrospectively, we analyzed 346 women diagnosed with breast tumors. Patients were divided according to the timing of
RESULTS
RESULTS
Median follow-up times were 131.42 and 93.77 months in the BRCA-preDx awareness and BRCA-postDx awareness groups, respectively. In the BRCA-preDx awareness group, 78.7% of the patients had invasive tumors and 21.3% were diagnosed with pure ductal carcinoma
CONCLUSIONS
CONCLUSIONS
High-risk screening might facilitate downstaging of detected breast tumor among
Identifiants
pubmed: 34540661
doi: 10.3389/fonc.2021.683656
pmc: PMC8443779
doi:
Types de publication
Journal Article
Langues
eng
Pagination
683656Informations de copyright
Copyright © 2021 Shraga, Grinshpun, Zick, Kadouri, Cohen, Maimon, Adler-Levy, Zeltzer, Granit, Maly, Carmon, Meiner, Sella, Hamburger and Peretz.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Natl Cancer Inst. 2000 Sep 20;92(18):1533-4
pubmed: 10995812
Cancer. 2011 Sep 1;117(17):3900-7
pubmed: 21365619
J Clin Oncol. 2014 Jul 20;32(21):2224-30
pubmed: 24934793
Clin Radiol. 2016 Nov;71(11):1143-7
pubmed: 27542654
Hered Cancer Clin Pract. 2016 Apr 14;14:8
pubmed: 27087880
J Clin Oncol. 2011 May 1;29(13):1664-9
pubmed: 21444874
Breast Care (Basel). 2015 Feb;10(1):13-20
pubmed: 25960720
J Natl Compr Canc Netw. 2021 Jan 06;19(1):77-102
pubmed: 33406487
J Epidemiol Community Health. 1998 Apr;52(4):267-71
pubmed: 9616416
Breast Cancer Res Treat. 2019 May;175(1):217-228
pubmed: 30725383
Cancer. 2013 Mar 15;119(6):1266-76
pubmed: 23184400
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Obstet Gynecol. 2010 Dec;116(6):1410-1421
pubmed: 21099612
JAMA. 2019 Aug 20;322(7):666-685
pubmed: 31429902
Lancet. 2005 May 21-27;365(9473):1769-78
pubmed: 15910949
Int J Cancer. 2015 Oct 1;137(7):1729-38
pubmed: 25820931
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
Nucl Med Rev Cent East Eur. 2017;20(1):45-48
pubmed: 28218347
J Natl Cancer Inst. 2001 Jul 18;93(14):1095-102
pubmed: 11459871
JAMA Oncol. 2020 Sep 1;6(9):1460-1463
pubmed: 32644100
Cancer. 2012 Apr 15;118(8):2021-30
pubmed: 21935911
J Natl Cancer Inst. 2004 Oct 6;96(19):1432-40
pubmed: 15467032
CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89
pubmed: 17392385
Int J Cancer. 2002 Nov 1;102(1):91-5
pubmed: 12353239
JAMA. 2005 Feb 23;293(8):931; author reply 931
pubmed: 15728161
Breast Cancer Res Treat. 2019 Feb;174(1):39-45
pubmed: 30474778
Am J Epidemiol. 2008 Jul 1;168(1):98-104
pubmed: 18504245